MedTrace Logo

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-12-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin

Conditions

  • Type II Diabetes

Interventions

DRUG

AZD1656

Tolerable dose given twice daily

DRUG

Placebo

Tolerable dose given twice daily

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof. · AstraZeneca R&D Mölndal

  • Marcus Hompesch, MD · Profil Institut for Clinical Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856908 on ClinicalTrials.gov